MAXCYTE, INC.
MXCTNasdaqIndustrials · Services-Commercial Physical & Biological Research · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $21.0M | $22.2M | $19.5M | $28.7M | $21.6M | $15.5M |
| Operating income | −$51.9M | −$51.2M | −$48.3M | −$27.4M | −$18.2M | −$11.1M |
| Net income | −$44.6M | −$41.1M | −$37.9M | −$23.6M | −$19.1M | −$11.8M |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M | $51.8M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M | $18.6M |
| Equity | $171.5M | $206.3M | $232.2M | $254.0M | $262.9M | $33.2M |
| EPS (diluted) | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 | $-0.17 |
| Shares out. | 106.0M | 104.1M | 102.9M | 101.5M | 101.2M | 77.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −247.6%
- Net margin
- −213.0%
- Return on equity
- −26.0%
- Return on assets
- −22.0%
- Return on capital (ROCE)
- −27.6%
- Liabilities / assets
- 15.3%
- Debt / equity
- 0.18×
- Book value / share
- $1.62
- Revenue growth (YoY)
- −5.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.25safe
- Accruals / assets
- −5.0%clean
- Beneish M-Score
- -2.76normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ahuja ParmeetOfficer — Chief Financial Officer | Apr 15, 2026 | Grant | 187,500 | $0.00 |
| Masoud MaherOfficer — President and CEO | Mar 27, 2026 | Grant | 300,000 | $0.00 |
| Swirsky Douglas JOfficer — CHIEF FINANCIAL OFFICER | Mar 17, 2026 | Sell | 10,142 | $0.81 |
| Hemrajani RekhaDirector | Jun 25, 2025 | Sell | 10,684 | $2.09 |
| Swirsky Douglas JOfficer — CHIEF FINANCIAL OFFICER | Aug 13, 2025 | Buy | 50,000 | $1.29 |
| Masoud MaherOfficer — President and CEO | Aug 13, 2025 | Buy | 75,000 | $1.37 |
| Erck Stanley CDirector | Aug 13, 2025 | Buy | 100,000 | $1.37 |
| Douglas RichardDirector | Aug 13, 2025 | Buy | 80,000 | $1.39 |
| Brooke William WDirector | Aug 13, 2025 | Buy | 50,000 | $1.29 |
| Johnston John JosephDirector | Jun 18, 2025 | Grant | 29,210 | $0.00 |
| Hemrajani RekhaDirector | Jun 18, 2025 | Grant | 29,210 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.7M | 3.8 | -9.9% |
| Apr 30, 2026 | 5.2M | 8.2 | -3.1% |
| Apr 15, 2026 | 5.4M | 6.4 | -2.5% |
| Mar 31, 2026 | 5.6M | 5.8 | +1.1% |
| Mar 13, 2026 | 5.5M | 5.0 | -4.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 12, 2026
- Director / officer changeMar 27, 2026
- Results of operations · Regulation FD disclosureMar 24, 2026
- Delisting / listing-standard noticeMar 20, 2026
- Results of operationsJan 12, 2026
- Results of operations · Regulation FD disclosureNov 12, 2025
- Results of operationsNov 5, 2025
- Costs from exit or disposal · Regulation FD disclosureSep 22, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13DMay 14, 2026
- 10-QMay 13, 2026
- 8-KMay 12, 2026
- ARSApr 29, 2026
- DEFA14ADEFA 14AApr 29, 2026
- DEF 14AApr 29, 2026
- 4Apr 17, 2026
- S-8FORM S-8Apr 15, 2026
- 4Apr 10, 2026
- 3Apr 10, 2026
- SCHEDULE 13G/AApr 10, 2026
- 4FORM 4Mar 31, 2026
- 8-KMar 27, 2026
- SCHEDULE 13G/AMar 27, 2026
- 10-KMar 25, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.